Lilly has spent over $15.3 billion in 2026 on acquisitions (Centessa, Kelonia, Orna, etc.) and has another $2.8 billion pending, creating significant organizational, IT, and operational integration challenges that require external support.
Filing excerpt
We paid $13.3 billion in 2026 related to business development activity, primarily driven by the acquisitions of Centessa, Kelonia, Orna, Ventyx, and Ajax.
What this signalsFilings often name leadership changes, deals and spending plans.
Vendors
sec-10qrestructuringGet every 10-Q signal for Eli Lilly and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Eli Lilly this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/778fad12-fcd7-45b2-a1b1-c3f335b5d734 returns this record as JSON. POST /v1/companies/enrich returns every signal for lilly.com.
{
"signal_id": "778fad12-fcd7-45b2-a1b1-c3f335b5d734",
"signal_type": "sec-10q",
"signal_subtype": "restructuring",
"detected_at": "2026-08-11T08:09:31.99+00:00",
"company": {
"name": "Eli Lilly",
"domain": "lilly.com"
},
"data": {
"detail": "Lilly has spent over $15.3 billion in 2026 on acquisitions (Centessa, Kelonia, Orna, etc.) and has another $2.8 billion pending, creating significant organizational, IT, and operational integration challenges that require external support.",
"metrics": {
"timeframe": "current_year",
"dollar_context": "Paid for business development activity and acquisitions in 2026.",
"dollar_millions": 15300
},
"summary": "Spent over $15B on acquisitions in 2026, driving major integration costs and restructuring.",
"excerpts": "We paid $13.3 billion in 2026 related to business development activity, primarily driven by the acquisitions of Centessa, Kelonia, Orna, Ventyx, and Ajax.",
"relevance": 0.9,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm",
"filing_date": "2026-08-05",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "06/30",
"sales_relevance": "Change management needs",
"signal_category": "workforce",
"vendors_mentioned": [
"Centessa Pharmaceuticals",
"Kelonia Therapeutics",
"Orna Therapeutics Inc.",
"Ventyx Biosciences Inc",
"Ajax Therapeutics Inc.",
"AtaiBeckley Inc.",
"Scorpion Therapeutics Inc"
]
}
}
curl https://signals.autobound.ai/v1/signals/778fad12-fcd7-45b2-a1b1-c3f335b5d734 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"lilly.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.